| Synonym |
| Thai / English name |
Part Used : ไม่ระบุActivity : CYP1A2 INHIBITIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12 (M/F=6/6)N(Treatment) : 12 (M/F=6/6)Sex : Both sexAge : 67+/-5.2 yrs.Route : Oral administrationDose/Conc.(herb) : 500 mg three times daily (standardized to 5% ginsenosides)Duration : 28 daysType of interaction : PharmacokineticsInteraction with drug : CaffeineDose/Conc.(drug) : 100 mgResult : PositiveRemark :Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.
Part Used : -Activity : CYP1A2 INHIBITIONSolvent/Active Compound : Ginsenoside R-Rh2Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-50 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark : The inhibitory potency of BST204 and its bioactive ginsenosides, R-Rg3, S-Rg3, R-Rh2 and S-Rh2, was determined using a nine-CYP isozyme cocktail assay in pooled human liver microsomes and IC50 values of ginsenoside S-Rg3 in reversible inhibition CYP450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5) was > micromolar.
Part Used : -Activity : CYP1A2 INHIBITIONSolvent/Active Compound : Ginsenoside S-Rg3Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-50 muMDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark : The inhibitory potency of BST204 and its bioactive ginsenosides, R-Rg3, S-Rg3, R-Rh2 and S-Rh2, was determined using a nine-CYP isozyme cocktail assay in pooled human liver microsomes and IC50 values of ginsenoside S-Rg3 in reversible inhibition CYP450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5) was > muM.
Part Used : -Activity : CYP1A2 INHIBITIONSolvent/Active Compound : Ginsenoside R-Rg3Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-50 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark : The inhibitory potency of BST204 and its bioactive ginsenosides, R-Rg3, S-Rg3, R-Rh2 and S-Rh2, was determined using a nine-CYP isozyme cocktail assay in pooled human liver microsomes and IC50 values of ginsenoside S-Rg3 in reversible inhibition CYP450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5) was > 50 microlar.
Part Used : -Activity : CYP1A2 INHIBITIONSolvent/Active Compound : Ginsenoside S-Rg3Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-50 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark : The inhibitory potency of BST204 and its bioactive ginsenosides, R-Rg3, S-Rg3, R-Rh2 and S-Rh2, was determined using a nine-CYP isozyme cocktail assay in pooled human liver microsomes and IC50 values of ginsenoside S-Rg3 in reversible inhibition CYP450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5) was > 50 micromolar.
Part Used : -Activity : CYP1A2 INHIBITIONSolvent/Active Compound : Ginsenoside S-Rh2Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-50 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark : The inhibitory potency of BST204 and its bioactive ginsenosides, R-Rg3, S-Rg3, R-Rh2 and S-Rh2, was determined using a nine-CYP isozyme cocktail assay in pooled human liver microsomes and IC50 values of ginsenoside S-Rg3 in reversible inhibition CYP450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5) was > 50 micromolar.
Part Used : -Activity : CYP1A2 INHIBITIONSolvent/Active Compound : BST204 (a purified dry extract of gineseng)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 0-50 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : EquivocalRemark : The inhibitory potency of BST204 and its bioactive ginsenosides, R-Rg3, S-Rg3, R-Rh2 and S-Rh2, was determined using a nine-CYP isozyme cocktail assay in pooled human liver microsomes and IC50 values of BST 204 in reversible inhibition CYP450 (CYP1A2, CYP2A6, CYP2C19, CYP2E1, and CYP3A4/5) was > 50 micromolar.
